BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold. 2023

Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, PR China.

Aim: In our study compounds with pyrido[3,2-d]pyrimidine and pyrido[3,4-d]pyrimidine were designed, synthesized and evaluated for their biological activity against hematologic tumors. Methods: The biological activity of compounds was evaluated by ADP-Glo Luminescence assay, MTT [3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide] assay, western blotting and flow cytometry, respectively. Results: Compounds A1, A5 and A7 containing pyrido[3,2-d]pyrimidine inhibited phosphoinositide 3-kinase-δ (PI3Kδ) at subnanomolar levels and had good δ-isoform selectivity. A1, A5 and A7 showed significant inhibitory effects against SU-DHL-6 cells and effectively inhibited Akt phosphorylation in a good concentration-dependent manner. A7 induced apoptosis and caused cell cycle arrest in SU-DHL-6 cells. Docking studies showed that A1, A5 and A7 bound tightly to PI3Kδ through key hydrogen bonding interactions. Conclusion: This study suggests that employing pyrido[3,2-d]pyrimidine can facilitate the design of novel potent and selective PI3Kδ inhibitors.

UI MeSH Term Description Entries
D011743 Pyrimidines A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D058534 Class I Phosphatidylinositol 3-Kinases A phosphatidylinositol 3-kinase subclass that includes enzymes with a specificity for 1-phosphatidylinositol, 1-phosphatidylinositol 4-phosphate, and 1-phosphatidylinositol 4,5-bisphosphate. Members of this enzyme subclass are activated by cell surface receptors and occur as heterodimers of enzymatic and regulatory subunits. Phosphatidylinositol 3-Kinase, Class I,Class I Phosphatidylinositol 3-Kinase,Class I Phosphatidylinositol 3 Kinase,Class I Phosphatidylinositol 3 Kinases,Phosphatidylinositol 3 Kinase, Class I
D062105 Molecular Docking Simulation A computer simulation technique that is used to model the interaction between two molecules. Typically the docking simulation measures the interactions of a small molecule or ligand with a part of a larger molecule such as a protein. Molecular Docking,Molecular Docking Simulations,Molecular Docking Analysis,Analysis, Molecular Docking,Docking Analysis, Molecular,Docking Simulation, Molecular,Docking, Molecular,Molecular Docking Analyses,Molecular Dockings,Simulation, Molecular Docking
D019869 Phosphatidylinositol 3-Kinases Phosphotransferases that catalyzes the conversion of 1-phosphatidylinositol to 1-phosphatidylinositol 3-phosphate. Many members of this enzyme class are involved in RECEPTOR MEDIATED SIGNAL TRANSDUCTION and regulation of vesicular transport with the cell. Phosphatidylinositol 3-Kinases have been classified both according to their substrate specificity and their mode of action within the cell. PI-3 Kinase,Phosphatidylinositol-3-OH Kinase,PtdIns 3-Kinase,PI 3-Kinase,PI-3K,PI3 Kinases,PI3-Kinase,Phosphoinositide 3 Kinases,Phosphoinositide 3-Hydroxykinase,PtdIns 3-Kinases,3-Hydroxykinase, Phosphoinositide,Kinase, PI-3,Kinase, Phosphatidylinositol-3-OH,Kinases, PI3,Kinases, Phosphoinositide 3,PI 3 Kinase,PI3 Kinase,Phosphatidylinositol 3 Kinases,Phosphatidylinositol 3 OH Kinase,Phosphoinositide 3 Hydroxykinase,PtdIns 3 Kinase,PtdIns 3 Kinases

Related Publications

Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and bioactivity evaluation of selenium-containing PI3Kδ inhibitors.
November 2023, Bioorganic chemistry,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Conformationally restricted quinazolone derivatives as PI3Kδ-selective inhibitors: the design, synthesis and biological evaluation.
March 2019, MedChemComm,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and biological evaluation of selective boron-containing thrombin inhibitors.
July 1999, Bioorganic & medicinal chemistry,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies.
May 2019, European journal of medicinal chemistry,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis, and biological activity of pyridopyrimidine scaffolds as novel PI3K/mTOR dual inhibitors.
February 2014, Journal of medicinal chemistry,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design of selective PI3Kδ inhibitors using an iterative scaffold-hopping workflow.
September 2019, Bioorganic & medicinal chemistry letters,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold.
July 2015, Organic & biomolecular chemistry,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.
November 2013, Bioorganic & medicinal chemistry letters,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and biological evaluation of selective survivin inhibitors.
April 2019, Journal of biomedical research,
Mengyan Ma, and Yifan Feng, and San-Qi Zhang, and Weiming Duan, and Li Gao, and Bo Yuan, and Minhang Xin
Design, synthesis and in vitro biological evaluation of 2-aminopyridine derivatives as novel PI3Kδ inhibitors for hematological cancer.
February 2023, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!